Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

ChemGenex Pharmaceuticals Limited announced today that the European Medicines Agency ("EMEA") has determined that the Marketing Authorization Application ("MAA") for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation is valid.

28 Nov 2009

Varian Medical Systems to exhibit its full range of detectors at RSNA Annual Meeting in Chicago

Varian Medical Systems, Inc., a premier supplier of X-ray tubes and flat panel digital image detectors, will exhibit its full range of detectors at the RSNA Annual Meeting in Chicago, Ill. from November 29 - December 3, 2009. Varian will also be exhibiting X-ray tube technology for multiple modalities as well as specialized cancer treatment technologies.

27 Nov 2009

GE Healthcare, MTL partner to manufacture diagnostic imaging products in Russia

GE Healthcare, a unit of General Electric Company, and a leading Russian medical imaging manufacturer Medical Technologies Limited (MTL), today announced a strategic partnership to manufacture diagnostic imaging products in Russia, starting with GE Healthcare’s CT BrightSpeed™ Elite system, in line with GE’s healthymagination strategy. The partnership will see Russia’s first locally manufactured advanced 16-slice computed tomography (CT).

26 Nov 2009

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

Idera Pharmaceuticals, Inc. today announced that Merck & Co., Inc., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and research collaboration agreement to research, develop, and commercialize vaccine products containing the Company’s investigational agonist compounds targeting Toll-like Receptors (TLRs) 7, 8, and 9 in the fields of oncology, infectious diseases, and Alzheimer’s disease.

26 Nov 2009

GIS scientists publish the first genetic historical map of Han Chinese

The first genetic historical map of the Han Chinese, the largest ethnic population in the world, as they migrated from south to north over evolutionary time was published online today by the American Journal of Human Genetics by scientists at the Genome Institute of Singapore (GIS).

26 Nov 2009

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.

26 Nov 2009

Advanced radiation delivery techniques can reduce TomoTherapy treatment time

TomoTherapy Incorporated announced today that a research study published in the November 11, 2009 International Journal of Radiation Oncology * Biology * Physics -- commonly known as the Red Journal -- indicated that TomoTherapy(SM) treatment times could be reduced by up to 66 percent using advanced radiation delivery techniques.

25 Nov 2009

Roche's xCELLigence RTCA DP Instrument with CIM-Plate 16 enables real-time monitoring of cell migration

Cell migration is an important process in the development of organisms, as well as during immune surveillance and wound healing. For cancer development, the potential of cells to migrate or to grow invasively is, in addition to proliferation, the most important disease-causing factor. The inhibition of cell migration is a key target of the new anti-inflammatory therapies.

25 Nov 2009

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

A recent study shows that 95 percent of radiation oncologists use advanced imaging techniques such as positron emission tomography (FDG-PET), magnetic resonance imaging (MRI), and 4-dimensional computed tomography (4DCT) for target delineation (to locate the tumor and other areas at risk for having cancer), according to an article in the December issue of the Journal of the American College of Radiology, (JACR, www.jacr.org).

25 Nov 2009

Incyte enters into collaboration and license agreement with Novartis

Incyte Corporation (NASDAQ: INCY) announced today that it has entered into a collaboration and license agreement with Novartis for two of its investigational hematology-oncology therapies: INCB18424, an oral JAK1/JAK2 inhibitor that is in Phase III development for myelofibrosis, a serious life-threatening neoplastic condition characterized by varying degrees of bone marrow failure, splenic enlargement and debilitating constitutional symptoms, and INCB28060, an oral cMET inhibitor that is about to enter Phase I development as a potential treatment for multiple cancers.

25 Nov 2009

Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced

Ipsen today announced the initiation of an international, multi-center, controlled, randomized Phase II clinical trial to evaluate the safety and efficacy of BN83495, its investigational first-in-class steroid sulfatase (STS) inhibitor, in advanced endometrial cancer.

25 Nov 2009

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

Gloucester Pharmaceuticals today announced multiple presentations from clinical and preclinical studies of ISTODAX® (romidepsin) at the upcoming 51st American Society of Hematology (ASH) Annual Meeting being held in New Orleans, Louisiana, at the Ernest N. Morial Convention Center, December 5 – 8, 2009.

25 Nov 2009

Eisai's NDA for Aricept tablets for treatment of Alzheimer's disease accepted for review

Eisai Inc. and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has accepted for review Eisai's New Drug Application (NDA) for once daily 23 mg Aricept® (donepezil HCl extended release) tablets for the treatment of moderate to severe Alzheimer's disease (AD).

25 Nov 2009

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced the issuance of a number of patents in Japan for its proprietary Mycobacterial Cell Wall-DNA Complex (MCC) composition.

25 Nov 2009

Positive efficacy data from Phase 2 study of AEZS-108 announced

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.

25 Nov 2009

Medical care in Germany for children with cancer is very good: IQWiG report

Internationally viewed, medical care in Germany for children with cancer is very good as far as survival is concerned. However, other aspects, such as quality of life, pain, and long-term consequences of the disease are still insufficiently investigated in studies. This is the conclusion of the Institute for Quality and Efficiency in Health Care (IQWiG) in its final report published on 16 October 2009.

25 Nov 2009

OmniComm Systems chosen as Beardsworth's preferred EDC provider

OmniComm Systems, Inc., one of the fastest growing companies in the EDC marketplace, today announced that Beardsworth, a full service contract research organization (CRO) who specializes in difficult therapeutic areas, has selected OmniComm's TrialMaster EDC solution for conducting a Phase II vaccine study.

24 Nov 2009

CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug

CytRx Corporation, a biopharmaceutical company, today announced plans to initiate a multinational Phase 2 clinical trial with its doxorubicin prodrug INNO-206 as a treatment for patients with advanced soft tissue sarcomas who have failed surgery and radiation. Soft tissue sarcomas are cancers that are formed in the muscle, fat, fibrous tissue, blood vessels or other supporting tissue of the body.

24 Nov 2009

Roche, Spanish Department of Health to collaborate in Medical Genome Project

Roche and the Department of Health of Junta de Andalucía, Spain have signed an agreement for a cooperation in the Medical Genome Project (MGP), a research project created to analyse the genomes of people with rare diseases and identify the defective gene or genes causing the disease and its behaviour.

From Roche Sequencing and Life Science 24 Nov 2009

Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study

Æterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with advanced or recurrent endometrial cancer.

24 Nov 2009

Oncology News and Research

Further Reading

EMEA determines MAA for omacetaxine mepesuccinate for treatment of CML patients

Varian Medical Systems to exhibit its full range of detectors at RSNA Annual Meeting in Chicago

GE Healthcare, MTL partner to manufacture diagnostic imaging products in Russia

Merck, Idera Pharmaceuticals extend their vaccine research collaboration

GIS scientists publish the first genetic historical map of Han Chinese

Wnt and EGFR signaling pathways interact to promote tumor cell invasion and metastasis

Advanced radiation delivery techniques can reduce TomoTherapy treatment time

Roche's xCELLigence RTCA DP Instrument with CIM-Plate 16 enables real-time monitoring of cell migration

Study shows 95 percent of radiation oncologists use FDG-PET, MRI and 4DCT to locate cancer

Incyte enters into collaboration and license agreement with Novartis

Initiation of Phase II clinical trial to evaluate the efficacy of BN83495 announced

Multiple presentations from clinical and preclinical studies of ISTODAX to be presented

Eisai's NDA for Aricept tablets for treatment of Alzheimer's disease accepted for review

Bioniche Life Sciences announces the issuance of MCC patents in Japan

Positive efficacy data from Phase 2 study of AEZS-108 announced

Medical care in Germany for children with cancer is very good: IQWiG report

OmniComm Systems chosen as Beardsworth's preferred EDC provider

CytRx to initiate a multinational Phase 2 clinical trial of its doxorubicin prodrug

Roche, Spanish Department of Health to collaborate in Medical Genome Project

Positive data from Æterna Zentaris' Phase 2 targeted cytotoxic peptide conjugate study

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News